'Hippocampal innate inflammatory gliosis only' in pharmacoresistant temporal lobe epilepsy.
epilepsy surgery
gliosis only
innate inflammation
neuropsychology
seizure outcome
Journal
Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537
Informations de publication
Date de publication:
13 02 2023
13 02 2023
Historique:
received:
04
01
2022
revised:
03
07
2022
accepted:
31
07
2022
pubmed:
19
8
2022
medline:
16
2
2023
entrez:
18
8
2022
Statut:
ppublish
Résumé
Drug-resistant mesial-temporal lobe epilepsy is a devastating disease with seizure onset in the hippocampal formation. A fraction of hippocampi samples from epilepsy-surgical procedures reveals a peculiar histological pattern referred to as 'gliosis only' with unresolved pathogenesis and enigmatic sequelae. Here, we hypothesize that 'gliosis only' represents a particular syndrome defined by distinct clinical and molecular characteristics. We curated an in-depth multiparameter integration of systematic clinical, neuropsychological as well as neuropathological analysis from a consecutive cohort of 627 patients, who underwent hippocampectomy for drug-resistant temporal lobe epilepsy. All patients underwent either classic anterior temporal lobectomy or selective amygdalohippocampectomy. On the basis of their neuropathological exam, patients with hippocampus sclerosis and 'gliosis only' were characterized and compared within the whole cohort and within a subset of matched pairs. Integrated transcriptional analysis was performed to address molecular differences between both groups. 'Gliosis only' revealed demographics, clinical and neuropsychological outcome fundamentally different from hippocampus sclerosis. 'Gliosis only' patients had a significantly later seizure onset (16.3 versus 12.2 years, P = 0.005) and worse neuropsychological outcome after surgery compared to patients with hippocampus sclerosis. Epilepsy was less amendable by surgery in 'gliosis only' patients, resulting in a significantly worse rate of seizure freedom after surgery in this subgroup (43% versus 68%, P = 0.0001, odds ratio = 2.8, confidence interval 1.7-4.7). This finding remained significant after multivariate and matched-pairs analysis. The 'gliosis only' group demonstrated pronounced astrogliosis and lack of significant neuronal degeneration in contrast to characteristic segmental neuron loss and fibrillary astrogliosis in hippocampus sclerosis. RNA-sequencing of gliosis only patients deciphered a distinct transcriptional programme that resembles an innate inflammatory response of reactive astrocytes. Our data indicate a new temporal lobe epilepsy syndrome for which we suggest the term 'Innate inflammatory gliosis only'. 'Innate inflammatory gliosis only' is characterized by a diffuse gliosis pattern lacking restricted hippocampal focality and is poorly controllable by surgery. Thus, 'innate inflammatory gliosis only' patients need to be clearly identified by presurgical examination paradigms of pharmacoresistant temporal lobe epilepsy patients; surgical treatment of this subgroup should be considered with great precaution. 'Innate inflammatory gliosis only' requires innovative pharmacotreatment strategies.
Identifiants
pubmed: 35978480
pii: 6670902
doi: 10.1093/brain/awac293
pmc: PMC9924906
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
549-560Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.
Références
Cell. 2015 Dec 17;163(7):1730-41
pubmed: 26686654
Neurology. 2016 Nov 1;87(18):1934-1942
pubmed: 27694267
Epilepsia. 2020 Jun;61(6):1211-1220
pubmed: 32363598
Acta Neuropathol Commun. 2021 Jan 6;9(1):3
pubmed: 33407896
Epilepsy Res. 2011 Nov;97(1-2):146-56
pubmed: 21873031
J Neuroimmunol. 2017 Dec 15;313:82-88
pubmed: 29153613
Zentralbl Neurochir. 2002;63(3):106-10
pubmed: 12457335
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
Neuroradiology. 2018 Feb;60(2):161-168
pubmed: 29085967
Epilepsia. 2009 Jun;50(6):1484-90
pubmed: 19292759
Nat Commun. 2019 Jun 11;10(1):2541
pubmed: 31186414
Epileptic Disord. 2011 Sep;13(3):263-76
pubmed: 21914589
Brain Cogn. 1997 Oct;35(1):110-31
pubmed: 9339305
Mol Neurobiol. 2019 Mar;56(3):1825-1840
pubmed: 29934763
Trends Neurosci. 2013 Mar;36(3):174-84
pubmed: 23298414
Fortschr Neurol Psychiatr. 2009 Dec;77(12):691-8
pubmed: 19950045
Epilepsia. 2008 Jan;49(1):88-97
pubmed: 17941848
Synapse. 2009 Nov;63(11):1017-28
pubmed: 19623530
Neuroimage Clin. 2020;27:102341
pubmed: 32707534
J Neurol Neurosurg Psychiatry. 2016 Apr;87(4):379-85
pubmed: 25855399
J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):894-9
pubmed: 19357127
Cortex. 1991 Dec;27(4):547-55
pubmed: 1782789
N Engl J Med. 2001 Aug 2;345(5):311-8
pubmed: 11484687
Lancet Neurol. 2020 Sep;19(9):748-757
pubmed: 32822635
J Mol Neurosci. 2012 Feb;46(2):420-6
pubmed: 21826395
J Neurol. 2015 Oct;262(10):2214-24
pubmed: 26138541
Epilepsia. 2013 Jul;54(7):1315-29
pubmed: 23692496
Neuroradiology. 2009 Jul;51(7):433-43
pubmed: 19242688
Acta Neuropathol. 2009 May;117(5):535-44
pubmed: 19277686
Neuropathol Appl Neurobiol. 2014 Aug;40(5):520-43
pubmed: 24762203
Epilepsia. 2004 Aug;45(8):960-2
pubmed: 15270763
JAMA Neurol. 2014 Jun;71(6):702-9
pubmed: 24781216
Cereb Cortex. 2022 Apr 20;32(9):1882-1893
pubmed: 34515307
N Engl J Med. 2017 Oct 26;377(17):1648-1656
pubmed: 29069555
Epilepsia. 1996 Feb;37(2):171-80
pubmed: 8635428
J Neurosurg. 2002 Nov;97(5):1131-41
pubmed: 12450036